{"id":"xolaam","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Nervousness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug activates beta-2 adrenergic receptors, leading to increased intracellular cAMP levels and smooth muscle relaxation in the airways. This results in sustained bronchodilation and improved lung function. Xolaam is formulated as a long-acting agent designed to provide extended therapeutic effect over 12-24 hours.","oneSentence":"Xolaam is a long-acting beta-2 agonist that binds to beta-2 adrenergic receptors on airway smooth muscle to promote bronchodilation and improve airflow in respiratory disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:39:34.748Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"},{"name":"Asthma (maintenance therapy)"}]},"trialDetails":[{"nctId":"NCT00444275","phase":"PHASE4","title":"Nexium (Esomeprazole) in Symptom Adapted Therapy in GERD Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-03","conditions":"GERD","enrollment":3029}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Xolaam®","genericName":"Xolaam®","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Xolaam is a long-acting beta-2 agonist that binds to beta-2 adrenergic receptors on airway smooth muscle to promote bronchodilation and improve airflow in respiratory disease. Used for Chronic obstructive pulmonary disease (COPD), Asthma (maintenance therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}